Table 2 Spearman's correlation between ORIDL and SF-12, MYMOP, and PEI at GHH (study 2)
From: Outcome related to impact on daily living: preliminary validation of the ORIDL instrument
|  | ORIDL – main complaint | ORIDL – well being | ||||
|---|---|---|---|---|---|---|
| Â | 3 months | 12 months | 33 months | 3 months | 12 months | 33 months |
SF-12 PCS Change | 0.214* (90) | 0.186 (56) | 0.224 (63) | 0.211* (90) | 0.152 (57) | 0.336** (63) |
SF-12 MCS Change | 0.245* (90) | 0.015 (56) | 0.334** (63) | 0.235* (90) | 0.040 (57) | 0.388** (63) |
MYMOP Change inProfile | 0.444*** (90) | 0.474*** (61) | 0.499** *(68) | 0.400** (99) | 0.487** *(62) | 0.541*** (68) |
MYMOP Change in Symptoms | 0.433*** (109) | 0.444** *(68) | 0.440 ** *(70) | 0.435** *(109) | 0.485*** (69) | 0.446***(70) |
MYMOP Change in Well-Being | 0.334** (102) | 0.314* (62) | 0.390** (64) | 0.333** (101) | 0.439** *(63) | 0.383** (64) |
PEI Overall Outcome | 0.451** (105) | 0.586***(62) | - | 0.528*** (104) | 0.640*** (63) | - |